Schnabel R, Rambeck B, May T W, Jürgens U, Lahl R
Institute of Neuropathology, v. Bodelschwinghsche Anstalten Bethel, Bielefeld, FRG.
Eur Neurol. 1994;34(4):213-20. doi: 10.1159/000117041.
Concentrations of carbamazepine (CBZ) and its metabolite carbamazepine-10, 11-epoxide (CE) were determined in serum (free and total), brain tumors and paratumorous cortex from 37 epileptic patients. Tumor biopsies were available from 25 different gliomas, 5 hamartomas and 1 angioma. The free serum concentrations of CBZ and CE were highly correlated with the corresponding paratumorous concentrations (r = 0.94 and r = 0.93) and to a lower extent with the tumorous concentrations (r = 0.78 and r = 0.75). For CBZ the concentration ratios paratumorous cortex/serum free and tumor/serum free showed no significant differences between CBZ-resistant and -nonresistant patients. Apart from histological grade a significant influence of type and site of the tumors on their CBZ and CE concentration was not recognizable. The results indicate that resistance to CBZ therapy cannot be sufficiently explained by decreased paratumorous or tumorous levels of CBZ and CE.
测定了37例癫痫患者血清(游离和总浓度)、脑肿瘤及瘤旁皮质中卡马西平(CBZ)及其代谢产物卡马西平-10,11-环氧化物(CE)的浓度。从25例不同的胶质瘤、5例错构瘤和1例血管瘤获取了肿瘤活检组织。CBZ和CE的血清游离浓度与相应的瘤旁浓度高度相关(r = 0.94和r = 0.93),与肿瘤浓度的相关性较低(r = 0.78和r = 0.75)。对于CBZ,瘤旁皮质/血清游离和肿瘤/血清游离的浓度比在CBZ耐药和非耐药患者之间无显著差异。除组织学分级外,未发现肿瘤类型和部位对其CBZ和CE浓度有显著影响。结果表明,CBZ治疗耐药不能充分用瘤旁或肿瘤中CBZ和CE水平降低来解释。